Medpace Holdings stock
Price history
+10.27% over the period1 year: from $585.76 (November 17, 2025) to $645.90 (November 17, 2026), +10.27%.
Show chart data
Closing prices adjusted for splits: the last close of each month.
| Date | Close |
|---|---|
| November 17, 2026 | $645.90 |
| October 30, 2026 | $652.01 |
| September 30, 2026 | $624.18 |
| August 31, 2026 | $593.99 |
| July 31, 2026 | $577.11 |
| June 30, 2026 | $529.59 |
| May 29, 2026 | $447.11 |
| April 30, 2026 | $418.66 |
| March 31, 2026 | $480.19 |
| February 27, 2026 | $451.76 |
| January 30, 2026 | $582.48 |
| December 31, 2025 | $561.65 |
| November 28, 2025 | $592.46 |
| November 17, 2025 | $585.76 |
At a glance
The company
Provides clinical research services supporting drug and medical device development from Phase I to Phase IV across multiple therapeutic areas
Latest results
Quarter to September 30, 2026 · EPS $4.84 (estimate $4.44)
TickerLandia's take on Medpace Holdings
- Pricier than usual relative to earnings: P/E on the latest fiscal year 42 vs a median of 35 over its last 10 fiscal years.
- Priced in line with similar companies: trailing 12-month P/E 36 vs 36 (+0%) in a group of 9.
Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks
Where the price stands
−5.89% from the 52-week high
Analysts · 14 analysts
Average target$651.31−0.27% vs. price
Buy 2 · Hold 11 · Sell 1
TickerLandia Fingerprint: Medpace Holdings
Compared with similar companies: very high profitability.
Financials and price compared with 27 companies in the diagnostics & research industry, worldwide. Momentum and risk compared with 883 North American stocks.
Pricehigh76
How much it costs relative to what it produces.
Metric Value Position in group P/E (trailing 12 months) 36.3 56 Forward P/E 32.9 94 EV/EBITDA 27.7 77 Price/book 31.2 94 Price/sales 6.44 61 Profitabilityvery high84
How much it earns on revenue and capital.
Metric Value Position in group Gross margin 72.2% 94 Net margin 18.2% 76 ROE 117.9% 94 ROA 18.7% 91 Operating margin 21.4% 65 Earnings stabilityhigh69
How steady its margins were over the last five annual reports.
Metric Value Position in group Margin variabilitycounts in reverse: lower means more earnings stability 1.8% 76 Loss-making yearscounts in reverse: lower means more earnings stability 0 of 5 annual reports 61 Growthhigh64
How fast revenue and earnings are growing.
Metric Value Position in group Revenue growth (year over year) +8.50% 50 Average revenue growth (3 years) +20.12% 83 Earnings growth (year over year) +25.40% 60 Financial strengthaverage60
How well it would weather a hard period: debt, liquidity, interest.
Metric Value Position in group Net debt/EBITDAcounts in reverse: lower means more financial strength · more cash than debt −0.64 90 Debt/equitycounts in reverse: lower means more financial strength 0.29 80 Current ratio 0.83 9 Dividendno dividend
How much it returns to shareholders, and for how long.
Market momentumstrong80
How the stock has moved compared with the market.
Metric Value Position in group Relative strength (3 months) +14.22% 81 Relative strength (6 months) +57.10% 97 1-year return +11.49% 49 Distance from 200-day average +22.61% 93 Riskaverage52
How much the price swings.
Metric Value Position in group Maximum drawdown (12 months) 36.6% 67 Volatility (60 days) 30.1% 39 Beta (1 year) 0.71 52
Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 18, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated
Valuation
Medpace Holdings is pricier than in the past and in line with similar companies
On the latest fiscal year's earnings (2025), Medpace Holdings's P/E today is 42.3, above the median of its last 10 fiscal years (35.4; between 26.3 and 97.5 from 2016 to 2025). Medpace Holdings's P/E (trailing 12 months): 36.3, in line with the median of a group of 9 similar companies (36.3).
Compared with 9 similar companies
| Metric | Medpace Holdings | Position in the group | Band |
|---|---|---|---|
| P/E (trailing 12 months) | 36.3 | Middle | |
| Forward P/E | 32.9 | High | |
| Operating margin | 21.4% | High | |
| ROE | 117.9% | High | |
| Debt/equity | 0.29 | Low |
P/E at fiscal year end; today on the latest fiscal year's earnings. Grey band: the middle half of the group; tick: the median; dot: Medpace Holdings. All multiples and dividends
TickerLandia analysisHow it is calculated
The financials
The business in numbers
Revenue
$716M
Latest quarter · Q3 2026
Net income
$137.46M
Latest quarter · Q3 2026
Quarterly net margin
19.2%
Latest quarter · Q3 2026
Numbers and valuation
Full valuation- Market cap
- $18.27B
- P/E
- 36.3
- EPS
- $18.01
- Volume
- 175.85K
- Daily trading
- €177.03M
- Dividend yield
- 0.00%
How Medpace Holdings is changing
All resultsRevenue grew 22.3% a year on average over the last 5 years
Operating margin rose from 19.1% to 21.1%
Profits turn into cash: free cash flow equal to 145% of net income
Returns
Medpace Holdings returns
$1,000 invested in Medpace Holdings 5 years ago, on November 17, 2021, would be worth $2,840 today: +184.02% in total, +23.22% per year. This is the price return only: dividends are excluded.
| Period | Medpace Holdings | S&P 500 | $1,000 becomes |
|---|---|---|---|
| 1 month | +4.23% | −3.17% | $1,042 |
| 6 months | +57.27% | +0.11% | $1,573 |
| Year to date | +15.00% | +8.34% | $1,150 |
| 1 year | +10.27% | +11.15% | $1,103 |
| 3 years | +135.72% | +64.30% | $2,357 |
| 5 years | +184.02% | +58.18% | $2,840 |
| 10 years | +1,701.17% | +239.10% | $18,012 |
Over the last 6 months it has done better than 92% of the stocks in the Healthcare sector.
Price only, without dividends. Calculate your investment
The chart in detail
Medpace Holdings: technical analysis
Medpace Holdings is in an uptrend: the price is above its 50- and 200-session moving averages, and the 200-session average is rising. The price is 5.7% below its all-time closing high ($692.68, October 28, 2026).
- Trend
- Upward
- RSI (14 sessions)
- 52
- Between 30 and 70
- vs 200-session average
- +22.61%
Support and resistance
Price areas where Medpace Holdings has stopped several times in the last year. They describe the chart; they are not forecasts.
- Resistance$678.54+3.90%2 touches, last on November 9, 2026
- Last price$653.09
- Support$630.92−3.39%5 touches, last on November 5, 2026
- Support$567.46−13.11%3 touches, last on August 17, 2026
- Support$530.96−18.70%2 touches, last on April 16, 2026
Volatility and risk
Over the last year it has moved less than the S&P 500.
- Beta (1 year) vs S&P 500
- 0.71
- Volatility (60 sessions, annualised)
- 30.1%
- Largest fall in the last year
- −36.61%
Close of November 17, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it
Medpace Holdings: seasonality
Average monthly price change over 11 years
Over the last 11 years, the strongest month for Medpace Holdings has been July: +14.23% on average, positive in 7 years out of 10. The weakest has been February: −3.54% on average, positive in 3 years out of 10. November, the current month, has been positive in 7 years out of 10 (+5.79% on average).
Show chart data
| Month | Average | Median | Positive years |
|---|---|---|---|
| January | +0.64% | +1.53% | 6 of 10 |
| February | −3.54% | −12.52% | 3 of 10 |
| March | +0.69% | +2.39% | 7 of 10 |
| April | −0.77% | +2.32% | 6 of 10 |
| May | +2.51% | +1.45% | 5 of 10 |
| June | +8.54% | +6.08% | 10 of 10 |
| July | +14.23% | +11.12% | 7 of 10 |
| August | +3.25% | +3.28% | 7 of 10 |
| September | +0.06% | +3.80% | 7 of 11 |
| October | +5.64% | +0.22% | 6 of 11 |
| November | +5.79% | +6.27% | 7 of 10 |
| December | +2.52% | +3.07% | 7 of 10 |
Price change only, dividends excluded. Past seasonality does not predict future moves.
The company
Medpace Holdings and its competitors
Clinical trial work for drug and medical device developers is delivered across Australia, Africa, South America, Asia, Europe and North America. The company runs studies from Phase I through Phase IV for pharmaceutical, biotechnology and medical device sponsors active in a broad set of therapeutic areas. Its range covers study design, central laboratory coordination, regulatory submissions, post-marketing support, bio-analytical laboratory services, clinical pharmacology, imaging and electrocardiography reading for trials.
- Headquarters
- Cincinnati, United States
- Employees
- 6,600
- Founded
- 1992
- Chief executive
- August Troendle
| Company | Market cap | Operating margin | P/E (trailing 12 months) | 6 months |
|---|---|---|---|---|
| Medpace HoldingsMEDP | $18.27B | 21.4% | 36.3 | +57.27% |
| RevvityRVTY | $17.84B | 16.3% | 70.5 | +57.27% |
| Guardant HealthGH | $20.52B | -39.4% | — | +50.95% |
| Charles River Laboratories InternationalCRL | $16.19B | 14.3% | 367.4 | +120.19% |
| ICON PublicICLR | $14.58B | 2.7% | 77.9 | +67.57% |
| Quest DiagnosticsDGX | $28.85B | 14.9% | 26.1 | +37.37% |
Same industry or related industries, similar size. Compare Medpace Holdings with its competitors · Full profile
